---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-25-000051"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T19:17:35.183703+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial; reports Q4 2024 net loss of $49.7M

## Summary
- BEACON-IPF discontinued after DSMB and outside expert panel recommendation due to imbalance in IPF-related adverse events; early efficacy on FVC observed.
- Q4 2024 net loss of $49.7M vs $41.1M in Q4 2023; R&D expenses increased to $38.8M from $33.2M.
- Cash, cash equivalents, restricted cash and short-term investments of $357.2M as of Dec 31, 2024; sufficient for 12+ months.
- Appointed Delphine Imbert, Ph.D. as Chief Technical Officer, previously at Chinook Therapeutics.
- Phase 1 trial of PLN-101095 in solid tumors continues; interim data from first three dose cohorts expected Q1 2025.

## SEC filing metadata
- accession: 0001746473-25-000051
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000051/0001746473-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000051/plrx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-25-000051
- JSON: https://secwatch.observer/filing/0001746473-25-000051.json
- Plain text: https://secwatch.observer/filing/0001746473-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.